Actxa, a Singapore-based preventive health brand committed to making preventive healthcare more accessible and actionable, will be participating in World Health Expo (WHX) Dubai 2026. At the event, Actxa will showcase its Core Smart Ring, featuring AI Glucose Scan capabilities designed to support everyday metabolic health awareness.
Actxa’s mission is simple but urgent – empower individuals with meaningful, health insights that enable earlier intervention and better long-term outcomes. By combining wearable technology, artificial intelligence and clinically backed technologies, Actxa aims to bridge the gap between everyday wellness tracking and true preventive care.
At WHX Dubai, Actxa will highlight the Core Smart Ring, a sleek and comfortable wearable designed for continuous lifestyle monitoring. Featuring AI Glucose Scan powered by Actxa’s proprietary BGEM® Glucose Status technology, the Core Smart Ring provides users with smarter insights related to glucose trends and metabolic patterns.
BGEM® is the world’s first non-invasive, AI-driven glucose evaluation technology, supported by clinical studies. By analysing photoplethysmography (PPG) data from the Core Smart Ring, BGEM® delivers meaningful, pain-free glucose insights without the need for needles or blood samples.
With a quick 1-minute scan, users receive a clear “Normal” or “Elevated” result linked to daily habits, with results syncing seamlessly to the Actxa App, where insights are presented through a clean, intuitive interface. Paired with lifestyle guidance that is easy to read and easy to act on, the Core Smart Ring supports smarter daily health decisions.
Actxa looks forward to partnership opportunities with:
Distributors expanding next-generation wearables across retail, pharmacy and healthcare channels
Healthcare and wellness partners exploring innovative solutions in metabolic health and preventive screening
Strategic partners and investors aligned with the convergence of AI, wearables and chronic disease prevention
Beyond the Core Smart Ring, Actxa continues to advance its BGEM® technology roadmap. This includes the development of Software as a Medical Device (SaMD) for BGEM® Diabetic Risk Assessment, designed to support detection and risk stratification of diabetes.
Actxa will also preview its upcoming BGEM® Range, a pain-free, one-minute measurement solution that provides dynamic blood glucose range insights, representing the next phase of its preventive health technology portfolio.